The post Kalshi and Polymarket weigh funding rounds at $20B valuations appeared on BitcoinEthereumNews.com. Prediction market platforms Kalshi and Polymarket areThe post Kalshi and Polymarket weigh funding rounds at $20B valuations appeared on BitcoinEthereumNews.com. Prediction market platforms Kalshi and Polymarket are

Kalshi and Polymarket weigh funding rounds at $20B valuations

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Prediction market platforms Kalshi and Polymarket are exploring fundraising rounds that could value each company near $20 billion, according to a Wall Street Journal report.

Both companies have recently held early discussions with potential investors about new funding rounds, according to people familiar with the matter. Each platform was last valued at roughly half that amount late last year.

The talks remain preliminary and may not lead to deals, and there is no guarantee either company will secure that valuation as scrutiny around prediction markets increases.

Kalshi already operates in the United States, offering markets on topics ranging from sports and politics to economic events and pop culture. The company was valued at about $11 billion after raising $1 billion in December from investors including Paradigm and Sequoia Capital.

Founded in 2018 by Tarek Mansour and Luana Lopes Lara, Kalshi became the first regulated exchange for event-based markets after receiving approval from the Commodity Futures Trading Commission in 2020.

The company recently surpassed a $1 billion annualized revenue run rate, with some estimates placing that figure closer to $1.5 billion.

Polymarket, founded in 2020 by Shayne Coplan, currently restricts US users but plans to launch a regulated domestic version of its platform this year.

The platform was last valued at about $9 billion in October after New York Stock Exchange owner Intercontinental Exchange agreed to invest up to $2 billion.

Both companies have recently faced scrutiny over markets tied to geopolitical events, including wagers on a potential US strike on Iran and the future of Iran’s Supreme Leader.

Lawmakers have also begun pushing for tighter oversight. US Representatives Blake Moore and Salud Carbajal introduced legislation aimed at restricting prediction markets from offering contracts tied to topics such as war and sports.

At the same time, both companies have aggressively pursued new users through social media advertising and campus outreach programs targeting college communities.

Disclosure: This article was edited by Estefano Gomez. For more information on how we create and review content, see our Editorial Policy.

Source: https://cryptobriefing.com/polymarket-fundraising-20b-valuation/

Market Opportunity
Ucan fix life in1day Logo
Ucan fix life in1day Price(1)
$0.0004868
$0.0004868$0.0004868
-6.65%
USD
Ucan fix life in1day (1) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09